Friday, January 20, 2012 8:30:22 AM
MNKD...$2.84...Chart...Please read this carefully especially the insider buys.This Biopharm company is a long term hold for me...very long term...like many Biopharms the price spikes on news of its drug trials...it is near its 52 week lows...a great entry point....read and make your choice but I see this as a $75 to $100 stock long term......
The last buy occurred when ALFRED E MANN purchased a total of 700,000 shares @ $5.25 on January 26, 2011. In the last 5 years insiders have on average purchased 4,376,279 shares each year
MannKind Corporation (MannKind) is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases, such as diabetes and cancer. The Company's product candidate, AFREZZA (insulin human) Inhalation Powder, is insulin that is in late-stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. AFREZZA utilizes its Technosphere formulation technology, which is based on a class of organic molecules that are designed to self-assemble into small particles onto which drug molecules can be loaded. With AFREZZA, the Company load recombinant human insulin onto the Technosphere particles; however, this technology is not limited to insulin delivery. In addition to the Technosphere platform, it is evaluating an investigational cancer immunotherapy product, MKC1106-MT, in a Phase II clinical trial.
I am personally a diabetic and have applied for entry in their clinical trials....
http://www.mannkindcorp.com
The last buy occurred when ALFRED E MANN purchased a total of 700,000 shares @ $5.25 on January 26, 2011. In the last 5 years insiders have on average purchased 4,376,279 shares each year
MannKind Corporation (MannKind) is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases, such as diabetes and cancer. The Company's product candidate, AFREZZA (insulin human) Inhalation Powder, is insulin that is in late-stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. AFREZZA utilizes its Technosphere formulation technology, which is based on a class of organic molecules that are designed to self-assemble into small particles onto which drug molecules can be loaded. With AFREZZA, the Company load recombinant human insulin onto the Technosphere particles; however, this technology is not limited to insulin delivery. In addition to the Technosphere platform, it is evaluating an investigational cancer immunotherapy product, MKC1106-MT, in a Phase II clinical trial.
I am personally a diabetic and have applied for entry in their clinical trials....
http://www.mannkindcorp.com
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
